Home
Diseases
Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Disease

Disease Profile

Chronic lymphocytic leukemia (CLL) is a slow-growing cancer of mature B lymphocytes in blood, bone marrow, and lymphoid tissues, most commonly affecting older adults.

Category: Hematologic malignancy (leukemia)
Prevalence: About 23,690 new cases of CLL are expected in the United States in 2025.

ICD Codes

C91.1

Related News

Chinese Biotech Exports Surge to $137.7B as U.S. Drugmakers Rush to Acquire Chinese Candidates

Jun 10, 2026

China's biotech overseas technology transfer agreements reached $137.7 billion in 2025, nearly ten times the 2021 figure, as global drugmakers rush to acquire Chinese candidates. BeiGene's Brukinsa surpassed $4 billion in global sales, while Pfizer agreed to a deal with Innovent Biologics worth up to $10.5 billion. U.S. lawmakers are raising security concerns about growing dependence on Chinese biotech.

Off-the-Shelf CAR-T Therapy CB-011 Shows High Response Rates in Multiple Myeloma; Broader CAR-T Advances Presented at 2026 Tandem Meetings

Jun 09, 2026

Updated data from the phase I CaMMouflage trial showed CB-011, the first allogeneic anti-BCMA CAR-T therapy with immune cloaking, achieved an approximately 92% overall response rate in relapsed/refractory multiple myeloma. The 2026 Tandem Meetings also highlighted advances in EB-103, KITE-753, and LV20.19 CAR-T constructs across lymphoma and CLL. Separately, NXC-201 reported a 95% complete response rate in AL amyloidosis.

FDA Approves Tecentriq for ctDNA-Guided Bladder Cancer and Venclexta Plus Acalabrutinib for CLL

May 16, 2026

FDA approves Genentech's Tecentriq as first ctDNA-guided adjuvant therapy for muscle-invasive bladder cancer, and Venclexta plus acalabrutinib as first all-oral fixed-duration regimen for CLL.

AbbVie raises 2026 guidance as Skyrizi and Rinvoq drive growth

May 05, 2026

AbbVie raised 2026 revenue and EPS guidance after first-quarter results beat estimates, with Skyrizi and Rinvoq driving growth. Humira erosion continued as neuroscience, oncology and pipeline assets supported the outlook.

BTKi Plus BCL-2i Combination Therapy in CLL: Safety, Lead-In Strategies, and Patient Counseling

Apr 29, 2026

Experts discuss balancing efficacy and safety in BTK inhibitor plus venetoclax combination therapy for CLL, including BTK lead-in strategies to reduce tumor lysis syndrome risk and the benefits of all-oral fixed-duration regimens.

AbbVie Files for SKYRIZI Subcutaneous Induction in Crohn's Disease

Apr 28, 2026

AbbVie filed an sBLA for SKYRIZI as a subcutaneous induction therapy for Crohn's disease, supported by Phase 3 AFFIRM data. SKYRIZI and Rinvoq combined for $25.9B in 2025 revenue, exceeding 2027 guidance. The FDA also approved Venclexta plus acalabrutinib in CLL.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07582159	Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	NOT_YET_RECRUITING	PHASE2
NCT07557056	Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	NOT_YET_RECRUITING	PHASE2
NCT07526597	Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors	NOT_YET_RECRUITING	PHASE2
NCT07520006	Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies	NOT_YET_RECRUITING	PHASE1/PHASE2
NCT07516093	Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL	NOT_YET_RECRUITING	PHASE3
NCT07474051	Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical Trials	ENROLLING_BY_INVITATION
NCT07463976	variaTIon in Referral Thresholds in the Chronic Lymphocytic LeukaEmia Pathway	NOT_YET_RECRUITING
NCT07412405	This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R	NOT_YET_RECRUITING	NA
NCT07321652	Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL	NOT_YET_RECRUITING	PHASE3
NCT07288515	Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus	RECRUITING